Rodriguez-Torres M, Yoshida EM, Marcellin P, Srinivasan S, Purohit VS, Wang C, Hammond JL

Idioma: Ingles.
Referencias bibliográficas: 13
Paginas: 364-375
Archivo PDF: 157.23 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Shi ST, Herlihy KJ, Graham JP, Nonomiya J, Rahavendran SV, Skor H, Irvine R, et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009; 53: 2544-52.

2. Wagner F, Thompson R, Kantaridis C, Simpson P, Troke P, Jagannatha S, Neelakantan S, et al. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir administered as monotherapy in HCV genotype 1 infected patients. Hepatology 2011; 54: 50-9.

3. Jacobson I, Pockros PJ, Lalezari, J, Lawitz E, Rodriguez- Torres M, DeJesus E, Haas F, et al. Virologic response rates following 4 weeks of filibuvir in combination with pegylated interferon alfa-2a and ribavirin in chronically-infected HCV genotype-1 patients. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of Liver (EASL); April 24-28, 2010; Vienna, Austria.

4. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Available from: http://www.wma.net/en/30publications/ 10policies/b3/index.html (accessed January 17, 2013).

5. Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob Agents Chemother 2012; 56: 1331-41.

6. Cochran WG. Some methods of strengthening the common χ2 tests. Biometrics 1954; 10: 417-51.

7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.

8. Jacobson IM, McHutchison JG, Dusheiko GM, Di Bisceglie AM, Reddy R, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C infection. N Engl J Med 2011; 364: 2405-16.

9. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns M, Sulkowski M, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.

10. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93. Erratum in: N Engl J Med 2009; 361: 1027.

11. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virologic response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55: 69-75.

12. Lawitz E, Rodriguez-Torres M, Rustgi VK, Hassanein T, Rahimy MH, Crowley CA, Freddo JL, et al. Safety and antiviral activity of ANA598 in combination with pegylated interferon á2A plus ribavirin in treatment-naive genotype-1 chronic HCV patients. Program and abstracts of the 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29-November 2, 2010; Boston, Massachusetts. Abstract 31.

13. Ferenci P, Nyberg A, Bernstein D, et al. PEARL III: SVR ≥ 99% after 12 wks of ABT-450/r/267 + ABT-333 ± RBV in treatment naive HCV GT1b infection. Conference on Retroviruses and Opportunistic Infections: March 3-6, 2014; Boston, Massachusettes. Abstract 29LB.